Global Clinical research Organisation (CRO) Company, ClinTec International, has expanded its operation to Malawi.

The company has also been chosen as a preferred partner by a top five pharmaceutical company with sales exceeding $50 billion, to develop vaccines in Africa and Asia. This will further enhance the company’s growth in emerging markets on the continent.

ClinTec is now appointing its first highly experienced clinical research associates, according to a statement released by the company, it is in the process of recruiting highly skilled personnel with vaccine research experience to join its already established teams in Africa and Asia, in preparation for strong growth ahead from these geographic markets.

Speaking on the new opening of the Malawi office, ClinTec’s President and CEO, Dr Rabinder Buttar said that the continued expansion in Africa will earn the company a huge potential in conducting large scale vaccine trials.

“Despite the challenging economic conditions through which many of our clients are restructuring their organisations, ClinTec continue to grow and win major new business from pharma companies’, Buttar remarked.

ClinTec is one of the first CROs to establish a presence in the Middle East and Africa and has continued to strengthen its presence in the emerging markets as well as the more traditional Western European clinical research marketplace.

ClinTec International has a presence in over 40 developed and emerging countries, covering Western Europe, Central & Eastern Europe, the Middle East and Africa, Central and South Africa, Latin America, Asia and the US.

With a strong and global reach across 80 countries, ClinTec has a wealth of experience in managing clinical trials in all major therapeutic categories including oncology, neurology, autoimmune diseases, orphan drugs and diabetes.